Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk

Yafei Li, Zhifu D Sun, Yanhong Wu, Dusica Babovic-Vuksanovic, Yan Li, Julie M Cunningham, Vernon S. Pankratz, Ping Yang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The cystic fibrosis transmembrane conductance regulator (CFTR) holds an important role in retaining lung function, but its association with lung cancer is unclear. A case-control study was conducted to determine the possible associations of the genetic variants in the CFTR gene with lung cancer risk. Genotypes of the most common deletion ΔF508, one functional SNP, and eight tag SNPs in the CFTR gene were determined in 574 lung cancer patients and 679 controls. A logistic regression model, adjusting for known risk factors, was used to evaluate the association of each variant with lung cancer risk, as confirmation haplotype and sub-haplotype analyses were performed ΔF508 deletion and genotypes with minor alleles in one tag SNP, rs10487372, and one functional SNP, rs213950, were inversely associated with lung cancer risk. The results of haplotype and sub-haplotype analyses were consistent with single variant analysis, all pointing to deletion ΔF508 being the key variant for significant haplotypes and sub-haplotypes. Individuals with 'deletion-T' (ΔF508/rs10487372) haplotype had a 68% reduced risk for lung cancer compared to common haplotype 'no-deletion-C' (OR=0.32; 95% CI=0.15-0.68; p=0.01). Genetic variations in the CFTR gene might modulate the risk of lung cancer. This study, for the first time, provides evidence of a protective role of the CFTR deletion carrier in the etiology of lung cancer.

Original languageEnglish (US)
Pages (from-to)14-21
Number of pages8
JournalLung Cancer
Volume70
Issue number1
DOIs
StatePublished - Oct 2010

Fingerprint

Cystic Fibrosis Transmembrane Conductance Regulator
Regulator Genes
Haplotypes
Lung Neoplasms
Mutation
Single Nucleotide Polymorphism
Logistic Models
Genotype
Case-Control Studies
Alleles
Lung

Keywords

  • Cystic fibrosis transmembrane conductance regulator
  • Genetic variation
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk. / Li, Yafei; Sun, Zhifu D; Wu, Yanhong; Babovic-Vuksanovic, Dusica; Li, Yan; Cunningham, Julie M; Pankratz, Vernon S.; Yang, Ping.

In: Lung Cancer, Vol. 70, No. 1, 10.2010, p. 14-21.

Research output: Contribution to journalArticle

@article{b3b2eb85f6c44d10979ba59087cbf893,
title = "Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk",
abstract = "The cystic fibrosis transmembrane conductance regulator (CFTR) holds an important role in retaining lung function, but its association with lung cancer is unclear. A case-control study was conducted to determine the possible associations of the genetic variants in the CFTR gene with lung cancer risk. Genotypes of the most common deletion ΔF508, one functional SNP, and eight tag SNPs in the CFTR gene were determined in 574 lung cancer patients and 679 controls. A logistic regression model, adjusting for known risk factors, was used to evaluate the association of each variant with lung cancer risk, as confirmation haplotype and sub-haplotype analyses were performed ΔF508 deletion and genotypes with minor alleles in one tag SNP, rs10487372, and one functional SNP, rs213950, were inversely associated with lung cancer risk. The results of haplotype and sub-haplotype analyses were consistent with single variant analysis, all pointing to deletion ΔF508 being the key variant for significant haplotypes and sub-haplotypes. Individuals with 'deletion-T' (ΔF508/rs10487372) haplotype had a 68{\%} reduced risk for lung cancer compared to common haplotype 'no-deletion-C' (OR=0.32; 95{\%} CI=0.15-0.68; p=0.01). Genetic variations in the CFTR gene might modulate the risk of lung cancer. This study, for the first time, provides evidence of a protective role of the CFTR deletion carrier in the etiology of lung cancer.",
keywords = "Cystic fibrosis transmembrane conductance regulator, Genetic variation, Lung cancer",
author = "Yafei Li and Sun, {Zhifu D} and Yanhong Wu and Dusica Babovic-Vuksanovic and Yan Li and Cunningham, {Julie M} and Pankratz, {Vernon S.} and Ping Yang",
year = "2010",
month = "10",
doi = "10.1016/j.lungcan.2010.01.005",
language = "English (US)",
volume = "70",
pages = "14--21",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Cystic fibrosis transmembrane conductance regulator gene mutation and lung cancer risk

AU - Li, Yafei

AU - Sun, Zhifu D

AU - Wu, Yanhong

AU - Babovic-Vuksanovic, Dusica

AU - Li, Yan

AU - Cunningham, Julie M

AU - Pankratz, Vernon S.

AU - Yang, Ping

PY - 2010/10

Y1 - 2010/10

N2 - The cystic fibrosis transmembrane conductance regulator (CFTR) holds an important role in retaining lung function, but its association with lung cancer is unclear. A case-control study was conducted to determine the possible associations of the genetic variants in the CFTR gene with lung cancer risk. Genotypes of the most common deletion ΔF508, one functional SNP, and eight tag SNPs in the CFTR gene were determined in 574 lung cancer patients and 679 controls. A logistic regression model, adjusting for known risk factors, was used to evaluate the association of each variant with lung cancer risk, as confirmation haplotype and sub-haplotype analyses were performed ΔF508 deletion and genotypes with minor alleles in one tag SNP, rs10487372, and one functional SNP, rs213950, were inversely associated with lung cancer risk. The results of haplotype and sub-haplotype analyses were consistent with single variant analysis, all pointing to deletion ΔF508 being the key variant for significant haplotypes and sub-haplotypes. Individuals with 'deletion-T' (ΔF508/rs10487372) haplotype had a 68% reduced risk for lung cancer compared to common haplotype 'no-deletion-C' (OR=0.32; 95% CI=0.15-0.68; p=0.01). Genetic variations in the CFTR gene might modulate the risk of lung cancer. This study, for the first time, provides evidence of a protective role of the CFTR deletion carrier in the etiology of lung cancer.

AB - The cystic fibrosis transmembrane conductance regulator (CFTR) holds an important role in retaining lung function, but its association with lung cancer is unclear. A case-control study was conducted to determine the possible associations of the genetic variants in the CFTR gene with lung cancer risk. Genotypes of the most common deletion ΔF508, one functional SNP, and eight tag SNPs in the CFTR gene were determined in 574 lung cancer patients and 679 controls. A logistic regression model, adjusting for known risk factors, was used to evaluate the association of each variant with lung cancer risk, as confirmation haplotype and sub-haplotype analyses were performed ΔF508 deletion and genotypes with minor alleles in one tag SNP, rs10487372, and one functional SNP, rs213950, were inversely associated with lung cancer risk. The results of haplotype and sub-haplotype analyses were consistent with single variant analysis, all pointing to deletion ΔF508 being the key variant for significant haplotypes and sub-haplotypes. Individuals with 'deletion-T' (ΔF508/rs10487372) haplotype had a 68% reduced risk for lung cancer compared to common haplotype 'no-deletion-C' (OR=0.32; 95% CI=0.15-0.68; p=0.01). Genetic variations in the CFTR gene might modulate the risk of lung cancer. This study, for the first time, provides evidence of a protective role of the CFTR deletion carrier in the etiology of lung cancer.

KW - Cystic fibrosis transmembrane conductance regulator

KW - Genetic variation

KW - Lung cancer

UR - http://www.scopus.com/inward/record.url?scp=77956190340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956190340&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2010.01.005

DO - 10.1016/j.lungcan.2010.01.005

M3 - Article

C2 - 20116881

AN - SCOPUS:77956190340

VL - 70

SP - 14

EP - 21

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -